-
-
-
-
-
-
-
Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band
-
-
-
-
-
-
-
Bernstein: 'We See Fresenius Medical Care (FMS) As a Tactical Buy After the Sell-Off'; PT Raised
-
-
-
-
-
-
-
Fresenius Medical Care delivers 18% earnings growth in 2024 and continues the acceleration momentum into 2025
-
-
-
-
-
-
-
Fresenius Medical Care (FMS) Tops Q4 EPS by 45c; offers outlook
-
-
-
-
-
-
-
Ozempic's early success in kidney disease trial drags down dialysis stocks
-
-
-
-
-
-
-
NxStage Reports Second Quarter Financial Results
-
-
-
-
-
-
-
Fresenius Medical (FMS) Tops Q2 EPS by 4c
-
1,222,535 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

